The treatment and management of tuberculosis using conventional drug delivery systems
remain challenging due to the setbacks involved. The lengthy and costly treatment regime …

Tuberculosis (TB) is a major global health problem and the second most prevalent infectious
killer after COVID-19. It is caused by Mycobacterium tuberculosis (Mtb) and has become …

Marketed dosage forms fail to deliver anti-tubercular drugs directly to the lungs in pulmonary
Tuberculosis (TB). Therefore, nanomediated isoniazid (INH)-loaded dry powder for …

Tuberculosis (TB) is one of the ten infectious diseases that cause the highest amount of
human mortality and morbidity. This infection, which is caused by a single pathogen …

Nanoparticles (NPs) have been widely used in different areas, including consumer products
and medicine. In terms of biomedical applications, NPs or NP-based drug formulations have …

Pulmonary delivery of antibiotics for the treatment of tuberculosis provides several benefits
compared to conventional oral and parenteral administration. API-loaded particles delivered …

Tuberculosis, a predominantly pulmonary pathology, is currently the deadliest infection
worldwide. Its treatment is based on combination therapy involving selected antimicrobials …

The global anxiety and economic crisis causes the deadly pandemic coronavirus disease of
2019 (COVID 19) affect millions of people right now. Subsequently, this life threatened viral …

In this era of advanced technology and innovation, infectious diseases still cause significant
morbidity and mortality, which need to be addressed. Despite overwhelming success in the …

In the current scenario, pulmonary disease has become a prime burden for morbidity and
mortality alongside tremendous social and economic crises throughout the world. Numerous …